Value of gene polymorphisms as markers of 5-FU therapy response in stage III colon carcinoma: a pilot study.

Abstract

PURPOSE:

The role of pharmacogenetics in chemotherapy response in colon carcinoma is controversial. We studied the value of known SNPs in genes involved in 5-FU metabolism as biomarkers of chemotherapy response in patients with stage III colon carcinoma.

METHODS:

DNA was isolated from normal colonic tissue of 60 patients with stage III colon carcinoma treated adjuvantly with 5-FU combined with leucovorin. The tested SNPs were validated SNPs on the OPRT, TYMS and DPYD genes and a synonymous SNP on the TYMP gene. Real-time PCR, sequencing and RFLP were used for genotyping.

RESULTS:

None of the studied genotypes was associated with any of the tumor or patient characteristics. Moreover, none of the genotypes studied had effect on patient survival.

CONCLUSION:

In conclusion, the tested SNPs are not biomarkers of chemotherapy response in our stage III colon cancer patients group.

• Authors: Arantza Fariña-Sarasqueta, Gesina van Lijnschoten, Harm J T Rutten, Adriaan J C van den Brule
• Journal: Cancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 66 Issue 6 Pg. 1167-71 (Nov 2010) ISSN: 1432-0843 [Electronic] Germany
• PMID: 20665215 (Publication Type: Journal Article)

Chemical References

• Antimetabolites, Antineoplastic
• Genetic Markers
• Fluorouracil

Topics

• Adult
• Aged
• Aged, 80 and over
• Antimetabolites, Antineoplastic (therapeutic use)
• Carcinoma (drug therapy, genetics, secondary)
• Colonic Neoplasms (drug therapy, genetics, pathology)
• Disease-Free Survival
• Female
• Fluorouracil (therapeutic use)
• Genetic Markers
• Humans
• Kaplan-Meier Estimate
• Male
• Middle Aged
• Neoplasm Staging
• Pilot Projects
• Polymorphism, Restriction Fragment Length
• Polymorphism, Single Nucleotide
• Treatment Outcome